Key Highlights
- Kent Rogers appointed as CEO and Josh Ofman, MD, MSHS as Chairman.
- First biotech company dedicated to personalized genetic medicines.
- Focus on antisense oligonucleotides (ASOs) for rare neurological diseases.
- Initial support from regulatory authorities for new therapy pathways.
- Founded with backing from Khosla Ventures, GV, and Third Rock Ventures.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Kent as CEO of EveryONE Medicines. With over 30 years of experience in product commercialization, supply chain logistics and market access strategy, Kent brings a wealth of knowledge and expertise to the team.” — Dr. Nessan Bermingham, Partner at Khosla Ventures
- “Our business model is unique to the industry, leveraging state-of-the-art genome sequencing, AI-driven innovation and advanced manufacturing capabilities.” — Kent Rogers, CEO at EveryONE Medicines
- “Technology is no longer the limiting factor. We can now find the underlying genetic cause of disease in children like Mila and develop a medicine that targets it, even if unique to one or just a few patients.” — Julia Vitarello, Co-founder at EveryONE Medicines
SoHC's Take
The appointment of Kent Rogers as CEO and Josh Ofman, MD, MSHS as Chairman marks a significant milestone for EveryONE Medicines, reinforcing their commitment to pioneering personalized genetic medicines. With substantial backing from renowned investment firms and regulatory support, the company is well-positioned to revolutionize the treatment of rare neurological diseases. By leveraging advanced technologies and innovative approaches, EveryONE Medicines aims to address critical unmet needs in the healthcare industry, offering hope to patients with unique genetic mutations. This strategic leadership change underscores the company’s dedication to making individualized treatments accessible and commercially viable, setting a new standard in the biotech sector.
